The remedy was intended to alleviate the suffering of coronavirus patients. Actemra / RoActemra (tocilizumab) from the Swiss pharmaceutical company Roche has been tested in several studies. Now the setback.

The goal was not achieved in the phase III study with the drug. The patient’s condition remains unchanged. But subordinate goals were also missed. For example, no difference in patient mortality was recognized in the fourth week.